JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Ingrezza revenue assumptions, expenses, and share count.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine board of directors authorizes $500M share repurchase program
- Promising Market Potential and Therapeutic Advancements Drive Buy Rating for Neurocrine’s Crenessity
- Buy Rating on Neurocrine Due to Stabilization Prospects and Competitive Landscape Opportunities
- Neurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY Launch
- Neurocrine’s Potential Upside: Buy Rating Amid Market Overreaction and Pipeline Prospects